MGMT and glioblastoma: The current analysis of GBM patients with MGMT promoter methylation receiving combined radiochemotherapy revealed that survival was prolonged in patients with a low CIN25 score (indicating a more stable genome) than those with a high score; in the latter group, the poor outcome was likely due in part to chemotherapy resistance arising from increased CIN.